Thu, February 5, 2009
Wed, February 4, 2009
Tue, February 3, 2009
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009
[ Fri, Jan 30th 2009 ] - Market Wire
Progen-Avexa Merger Update
Thu, January 29, 2009
Wed, January 28, 2009
Tue, January 27, 2009
[ Tue, Jan 27th 2009 ] - Market Wire
SCOR: SCOR sets up Zurich Hub
Mon, January 26, 2009
Sun, January 25, 2009
Fri, January 23, 2009
Thu, January 22, 2009
Wed, January 21, 2009

Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2009


//health-fitness.news-articles.net/content/2009/ .. al-results-for-third-quarter-of-fiscal-2009.html
Published in Health and Fitness on , Last Modified on 2009-01-29 15:10:18 by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. EST on Thursday, February 5, 2009 to discuss the company's financial results for its third quarter of fiscal 2009. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermes' website at [ www.alkermes.com ] or may be accessed by dialing 1-866-219-5260 for domestic callers and 1-703-639-1117 for international callers. The conference call ID number is 1328237.

A replay of the conference call will be available from 7:30 p.m. EST on Thursday, February 5, 2009 through 5:00 p.m. EST on Thursday, February 12, 2009, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 1328237. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Thursday, February 12, 2009.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in Ohio.


Publication Contributing Sources

Similar Health and Fitness Publications